We expect revenue and PAT CAGR of 15.9% and 15.3% respectively over the period FY21-FY23E and recommend a Buy with TP of INR 840.

Asian Markets: Asian markets are trading mixed as investors take note of Japan's first quarter GDP data which showed economy shrank at an annualized rate of 5.1% in January to March. Nikkei is trading higher by 2.04%, Shanghai is trading lower by 0.07% and Hang Seng is trading higher by 1.20%.

Maintain BUY with revised TP of Rs. 1,835 and continue to value it at 40x its FY23E EPS.

We believe Gland Pharma is well placed to grab upcoming opportunities in the injectables space in the US market and therefore recommend a "BUY" with TP of INR 3,200/share.

Asian markets are trading mixed as investors take note of data from China that showed that industrial output rose 9.8% yoy in April, in line with estimates while retail sales increased 17.7% yoy, below estimates of 24.9% increase. Nikkei is trading lower by 1.13%, Shanghai is trading higher by 0.70%

We recommend HOLD and assign 15x P/E multiple to its FY23E earnings of Rs. 18.8 per share to arrive at a TP of Rs. 285 per share, implying an upside of 6% from CMP.

We maintain our BUY recommendation on CFS and value the stock at 16x FY23E EPS to arrive at a TP of Rs. 184/share, implying an upside of 12% from CMP.

Therefore, we recommend Buy with a revised target price of INR 5,700.

We maintain our BUY rating on the stock but with a revised target price of Rs 1,350 (from Rs 1,600 earlier) valuing the company at 15x (from 17x earlier) FY23E P/E.

We recommend a BUY on the stock with a target price of Rs 1,400/share.

We revise our rating to BUY (HOLD earlier) given the long term structural growth drivers like ,clear focus on driving volumes and profitability, improved traction in other business segments

KEC International at 12x FY23E EPS of Rs.35.4 to arrive at a target price of Rs.424 implying an upside of 13% from CMP.

We recommend a BUY' with TP of INR 1,400/share, implying an upside of 15.7% from CMP.

We roll over our estimate to FY23E valuing the company at 7x of FY23E EV/EBITDA to arrive at target price of Rs, 1230 implying an upside of 18% from CMP.

Asian markets are trading higher tracking cues from Wall Street overnight. Nikkei is trading higher by 1.80%, Shanghai is trading higher by 0.64% and Hang Seng is trading higher by 0.46%.

Asian markets are trading mixed tracking cues from Wall Street overnight. Nikkei is trading lower by 0.59%, Shanghai is trading higher by 0.15% and Hang Seng is trading higher by 0.42%. Indian indices are expected to open on a flat note and focus will be on domestic data and quarterly earnings for f

We recommend a BUY and assign 58x P/E multiple to its FY23 EPS of Rs 104.4 per share to arrive at a TP of Rs 6,055/share, implying an upside of 15% from CMP.

We expect the company to post Revenues/EBIDTA/PAT at a CAGR of 34%/43%/139% respectively over FY20-23E. We retain a BUY with a revised target price of Rs 908/share(earlier target Rs 877/share), valuing the company at 4x EV/EBIDTA FY23E, giving an upside of 21% from CMP.

We revise our rating to Hold from Buy with a revised target price of 570 (3.7x FY23 P/ABV).

we revise our estimates and continue to maintain BUY rating with a target price of Rs. 325 (Previous TP Rs. 204) valuing it at 20x of FY23E EPS. The TP implies an upside potential of 10% from CMP.